Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qianliebeixi capsule is a Chinese Patent Medicine (CPM) primarily indicated for the treatment of chronic prostatitis and benign prostatic hyperplasia (BPH). It is a multi-ingredient herbal formulation composed of several traditional Chinese medicinal herbs, including *Lycopus lucidus*, *Vaccaria segetalis*, and *Astragalus membranaceus*. The drug is designed to alleviate symptoms such as pelvic pain, urinary frequency, and urgency by exerting anti-inflammatory and analgesic effects. Mechanistically, it works by improving local microcirculation in the prostate, reducing tissue edema, and modulating the levels of pro-inflammatory cytokines in the prostatic fluid. In clinical practice, it is often evaluated as a monotherapy or in combination with alpha-blockers like tamsulosin for National Institutes of Health (NIH) category III chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on qianliebeixi capsule.